The team first fed mice a high-fat diet and observed lower PQBP1 levels in the cerebral cortex, a brain region involved in cognitive functions. PQBP1 regulates alternative RNA splicing, a process that allows a single gene to generate different RNA transcripts and potentially different protein isoforms. The researchers linked the diet-associated reduction in PQBP1 to suppressed PPARγ-mediated transcription of the PQBP1 gene. They also implicated insulin-related signaling as a possible upstream mechanism, but the supplied study description does not establish whether that signaling change is a direct cause of the reduction.

To examine the cellular consequences, the scientists used RNA-sequencing-based analyses to compare splicing patterns in mice fed a high-fat diet for one or six weeks with those in mice lacking PQBP1 in neurons. Both conditions shared changes in the alternative splicing of specific genes associated with synaptic function. Additional experiments indicated that abnormal splicing of these downstream genes was associated with abnormalities in synaptic structure and function. These molecular and cellular changes occurred alongside impaired cognitive performance, linking diet-associated changes in gene regulation with impaired neuronal communication. The work was conducted in mice, and the reported effects should therefore not be interpreted as evidence that the same pathway causes cognitive decline in humans.

The researchers also tested whether selected molecular changes could be reversed in mice. Pioglitazone, a diabetes drug that activates PPARγ, restored PQBP1 levels in mice receiving the high-fat diet. It also corrected abnormal RNA splicing in key synapse-related genes and improved synaptic and cognitive outcomes. A separate gene-therapy approach that restored PQBP1 rescued synaptic and cognitive deficits, while restoring particular downstream genes also produced beneficial effects. These interventions were tested in the same experimental setting rather than in a human clinical trial, and their results show that the measured pathway can be modulated in affected mice. The findings identify PQBP1-dependent alternative RNA splicing as a potential therapeutic target for further investigation, but the study does not establish that pioglitazone or gene therapy is safe or effective for diet-associated cognitive impairment in people.

Subject of Research: Experimental mouse study of PQBP1-dependent RNA splicing in high-fat diet-induced cognitive impairment

Article Title: Exploring the correlation between high calorie diet and cognitive impairment

Article References: Exploring the correlation between high calorie diet and cognitive impairment. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: high-fat diet, cognitive impairment, PQBP1, RNA splicing, synaptic dysfunction, cerebral cortex, PPARγ, pioglitazone, gene therapy, mouse study, Exploring, correlation

The study used DeepLabCut to track the ears, nose and tail base of freely moving mice, then applied the SimBA machine-learning framework to classify feeding frame by frame. Investigators recorded four-hour sessions in an arena containing four food-bait containers, with standard chow available throughout. Before each session, mice were food-deprived for four hours while retaining access to water. The principal measure was the mean duration of feeding bouts for each mouse, calculated after feeding periods separated by gaps of less than seven seconds were merged. This per-mouse endpoint was intended to summarize temporal organization without treating individual bouts or video frames as independent biological replicates.

To evaluate the automated pipeline, researchers compared its bout-duration estimates with blinded manual scoring of the same recordings from 170 mice drawn from the intermittent high-fat diet, social-isolation and physical-restraint experiments. The two methods were positively associated, with an R² of 0.5819 and p<0.0001. That association supports the system’s usefulness for group-level quantification, but the scatter around the regression means that automated and manual estimates are not interchangeable for individual animals. The feeding classifier itself was trained on 8,992 manually annotated frames from one male mouse and achieved precision of 0.994, recall of 0.993 and an F1 score of 0.994 on a held-out test set. Because predictions for that training animal were not fully out of sample, it was excluded from the manual-versus-automated regression and the corresponding automated group comparison.

Social isolation was induced by housing wild-type C57BL/6J mice individually for seven days, while age-matched controls remained group-housed in groups of four. In the intermittent high-fat diet experiment, six-week-old mice received the diet for two hours every other day for two weeks; controls remained on standard chow. Both stressors significantly increased mean feeding-bout duration compared with their controls, with p-values of 0.0213 for isolation and 0.0110 for intermittent high-fat diet exposure. Manual scoring independently confirmed the pattern, yielding p-values of 0.0096 and p<0.0001, respectively. The number of bouts, latency to first feeding and mean interval between bouts did not change significantly in either comparison, indicating that the clearest detectable alteration concerned how long feeding episodes lasted once initiated.

These findings were not simply reflections of eating more food. The study’s earlier analysis of the same recordings found that intermittent high-fat diet exposure increased total intake in male mice, with a similar trend in females, whereas social isolation produced no consistent change in consumption. Yet both conditions prolonged individual bouts. Total feeding time was significantly greater in socially isolated mice, while the increase associated with intermittent high-fat diet exposure was numerically greater without reaching statistical significance. The experiments therefore suggest that intake and temporal feeding structure can dissociate: a mouse may consume a different quantity without exhibiting a different pattern of feeding episodes. This distinction matters because the authors argue that total consumption alone may miss stress-associated changes in the organization of reward-related behavior.

Physical restraint did not produce the same temporal effect. Seven-week-old mice were completely immobilized for two hours a day for five consecutive days before recording. Restrained mice had a slightly lower mean feeding-bout duration than controls, but the difference was not statistically significant, with p=0.1661; blinded manual scoring also found no significant difference. Restrained animals spent less total time feeding, while bout number, latency and inter-bout interval did not differ significantly. Because the primary comparison was not significant, restraint alone cannot be described as a robust inducer of protracted feeding under the conditions used. The authors suggest that the autonomic and gastrointestinal state produced by restraint may constrain sustained feeding or mask a stress-related temporal deviation, but the experiment did not directly measure either gastrointestinal motility or sympathetic activity.

To probe that possibility, the researchers administered mosapride, a peripheral 5-HT4 receptor agonist that promotes gastrointestinal motility, after restraint periods. In male mice already exposed to restraint, mosapride significantly increased mean feeding-bout duration compared with restraint plus control treatment, with p=0.0374, and increased total feeding time with p=0.0384. It did not significantly alter bout number, latency, inter-bout interval, spatial fixated-feeding behavior or total intake during the recording. The result is consistent with peripheral physiological state influencing the expression of a central feeding pattern, but it does not establish a specific autonomic mechanism. The absence of a non-stressed mosapride-treated group also prevents the investigators from determining whether the drug’s effect on bout duration is specific to restraint stress.

Central dopamine manipulation produced the clearest mechanistic evidence. In mice exposed to intermittent high-fat diet or social isolation, dopamine administered directly into the nucleus accumbens shell significantly reduced mean feeding-bout duration, with p=0.0332 and p=0.0440, respectively. Previously reported intake measurements from those same cohorts did not differ significantly between dopamine and vehicle treatment, reducing the likelihood that shorter bouts merely reflected reduced consumption. In a separate chemogenetic experiment, mice expressing the inhibitory designer receptor hM4Di in ventral tegmental area dopamine neurons received either clozapine-N-oxide or vehicle in a counterbalanced, within-subject design. Inhibition increased mean bout duration, with p=0.0360 in a paired test, even though it reduced total food intake, with p=0.0075. These complementary interventions implicate the ventral tegmental area–nucleus accumbens shell dopamine axis in maintaining the temporal organization of feeding.

Several limitations constrain how far the results can be generalized. Most recordings were originally acquired for an earlier study rather than collected in prospectively designed, independent cohorts, although the earlier investigators had not analyzed bout duration. Some experimental groups also underwent stereotaxic surgery, and the absolute bout-duration means differed across cohorts, so the study does not establish whether surgery shifted the entire distribution. The mosapride, nucleus accumbens and chemogenetic experiments included only male mice; sex-stratified results in the broader cohorts pointed in the same direction but were underpowered and cannot demonstrate equivalence between sexes. Standardized food deprivation standardized pre-recording access but did not guarantee equal hunger or satiety at the start of a session, particularly because the stress paradigms themselves could alter intake. The four-bait assay, mouse strains and laboratory environment also limit transfer to other behavioral settings, and the automated workflow has not been validated across a wider range of behaviors. Combining bout-duration measures with established compulsivity assays would be necessary to determine whether protracted feeding captures the same construct as inflexible or compulsive behavior.

For the scientists, the broader significance lies in a new behavioral readout that complements the group’s earlier description of fixated feeding, an abnormal preference for particular food locations. Fixated feeding concerns where a mouse feeds, whereas protracted feeding concerns how long each feeding episode persists. The automated workflow links the spatial and temporal dimensions of stress-related feeding to mesolimbic dopamine dysfunction without reducing either measure to the amount consumed. It also illustrates why machine-assisted behavioral analysis can uncover patterns that may be difficult to score consistently by hand, although human observers and the automated classifier are not interchangeable. The authors present protracted feeding as a candidate preclinical marker of stress-associated reward-system dysfunction, not as a clinical test or a demonstrated human symptom. Future work will need independent validation, direct measurements of peripheral state, broader behavioral sampling and testing in female mice to determine how robustly the phenotype and its proposed mechanisms generalize.

Subject of Research: Automated analysis of stress-related feeding patterns and mesolimbic dopamine in mice

Article Title: Automated temporal analysis reveals stress-induced protracted feeding regulated by mesolimbic dopamine in mice

Article References: Guo, X., Fujioka, Y., Kawai, K., & Ishigaki, S. (2026). Automated temporal analysis reveals stress-induced protracted feeding regulated by mesolimbic dopamine in mice. Frontiers in Neuroscience, 20, Article 1959447. https://doi.org/10.3389/fnins.2026.1959447

Image Credits: AI Generated

DOI: 10.3389/fnins.2026.1959447

Keywords: mouse feeding behavior, mesolimbic dopamine, nucleus accumbens, ventral tegmental area, social isolation, high-fat diet, physical restraint, DeepLabCut, SimBA, behavioral neuroscience, Automated, temporal

The study, published in the journal Science, identifies a cellular pathway controlled by the protein YAP1 as a necessary engine of colorectal cancer metastasis. YAP1 is no villain in healthy tissue. It normally drives organ development, stem cell maintenance and wound repair, switching on genes that allow the intestinal lining to rebuild itself after severe injury or infection. The MIT researchers found that colon cancer cells can co-opt this fetal-like repair state, using it to break free from the primary tumor, migrate through the body and colonize new organs.

“We’ve found a pathway that we think is druggable. If we shut down the enzymes that make ceramides, tumor cells can’t switch on this regenerative program, and they largely fail to seed metastases in the liver,” said Omer Yilmaz, director of the MIT Stem Cell Initiative, a professor of biology at MIT and a member of the Koch Institute for Integrative Cancer Research, who is also a gastrointestinal pathologist at Beth Israel Deaconess Medical Center.

The discovery emerged from a systematic search for epigenetic programs — patterns of gene activation and silencing that do not involve changes to the DNA sequence itself — that distinguish metastatic cells from those that stay put. Using tumor organoids, three-dimensional clusters of cancer cells grown in the laboratory, derived from mouse models of several colon cancer types and from patients with colorectal cancer, the team found that metastatic cells shared one defining feature: activation of the YAP1 program. In the gut, this program normally runs through a rare, fetal-like cell type that appears only briefly to regenerate the intestinal lining after damage. YAP1 has been linked to cancer for years, but the new work shows that diet-derived lipids can push tumor cells into this specific regenerative state, and that the state itself is what licenses metastasis.

“The regenerative program that we described is generally observed in the gut when there is severe injury or infection and the gut needs to regenerate. We see the tumor cells hijack this program to drive metastatic progression,” said Swagata Goswami, an MIT postdoctoral researcher and one of the study’s lead authors, alongside fellow postdocs Qiming Zhang and Abdullah Burak Yildiz.

The link to diet came as a striking surprise. In mouse experiments, cancer cells in animals fed a high-fat diet switched on YAP1 to a far greater extent than cells in mice eating a healthy diet. Tracing the mechanism, the researchers found that a fatty diet activates enzymes that produce ceramides, a class of lipid molecules best known for their role in skin barriers and cell signaling. Ceramides then release the molecular brake that normally keeps YAP1 inactive, freeing the protein to move into the cell’s nucleus and switch on its target genes. In other words, the fat on the plate is translated, molecule by molecule, into a genetic program that makes cancer mobile.

The therapeutic implications are considerable. When the researchers genetically targeted YAP1, or the genes involved in ceramide production, the spread of colon cancer to the liver in mice dropped markedly. That suggests a concrete intervention point: drugs that block ceramide synthesis, particularly by inhibiting two of the enzymes involved, known as DEGS1 and DEGS2, could potentially prevent metastasis in patients diagnosed with colon cancer. The team now plans to develop such inhibitors. Because ceramides are also essential in healthy tissues, any drug targeting their production will have to clear a high bar for selectivity, the researchers caution.

To determine whether the same program operates in humans, the team analyzed RNA sequencing data from patients with colorectal cancer. The pattern held. YAP1 was more active in metastatic cancer cells than in primary tumors, and patients with higher body mass index showed higher expression of the genes activated by YAP1 than patients of normal weight. Strikingly, patients with elevated levels of those YAP-driven genes also had lower survival rates, tying the molecular signature directly to clinical outcomes.

The findings may help explain a long-standing epidemiological observation: obesity is a known risk factor for the progression of colorectal cancer, but the mechanism has been murky. “We don’t think that the YAP1 program is specific to obesity. It’s just that it becomes accentuated in obesity, and that may account for why obesity is known to drive the progression of colorectal cancer,” Yilmaz said. In this framing, excess dietary fat does not create a new cancer program so much as amplify one that tumor cells are already poised to exploit.

The work also reframes how scientists think about metastasis itself. Many studies have searched for a genetic driver of spread and found none; there is no defining mutational signature that separates metastatic cells from the primary tumor. That absence, Yilmaz noted, points to metastasis being driven largely by changes in which genes are switched on and off, rather than by new mutations. If that is true, then the epigenetic and metabolic states of tumor cells — influenced by diet, inflammation and tissue environment — may be as important as the mutations that started the cancer in the first place. For the roughly one-third of patients with stage 2 or 3 colon cancer who relapse with metastatic disease even after successful surgery, a druggable pathway that blocks the seeding of liver metastases could transform the outlook for one of the world’s most common cancers. The researchers caution, however, that the findings do not yet translate into dietary advice for patients already diagnosed, and that clinical application will depend on the safety and selectivity of the ceramide-blocking drugs now in development.

Subject of Research: The role of YAP1 activation and ceramide synthesis in colorectal cancer metastasis

Article Title: Biologists identify a cellular pathway that allows colorectal cancer to metastasize

Article References: Biologists identify a cellular pathway that allows colorectal cancer to metastasize. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: colorectal cancer, metastasis, YAP1, ceramides, high-fat diet, obesity, liver metastasis, tumor organoids, epigenetics, regeneration, DEGS1, DEGS2

The study, published in Frontiers in Gastroenterology, took an unusual two-pronged approach known as triangulation, pairing a Mendelian randomization analysis of large genetic datasets with a retrospective clinical study of patients whose portal pressure was measured directly. The logic behind triangulation is simple but powerful: no single observational study can fully rule out confounding, so researchers seek multiple lines of evidence that rely on different assumptions. If independent methods converge on the same answer, the conclusion becomes far harder to dismiss as an artifact of bias.

Mendelian randomization exploits a quirk of biology: genes are randomly allocated at conception and remain fixed throughout life. By using genetic variants that predict dietary fat intake as instruments, researchers can approximate a randomized trial of lifelong eating habits without actually assigning diets. Because the genes are inherited randomly, they are largely immune to the confounding factors that plague ordinary nutrition studies, such as obesity, insulin resistance, or the tendency of advanced liver disease itself to change what people eat. The method rests on three assumptions: the genetic variants must be strongly associated with the exposure, must not be linked to confounders, and must influence the outcome only through the exposure.

In practice, the team drew on genome-wide association study data covering 268,922 people of European ancestry, selecting 18 independent single nucleotide polymorphisms associated with fat intake as a percentage of total energy consumption. These instruments were strong by conventional standards, with a mean F-statistic of 34.2 against the threshold of 10 usually required, though together they explained only 2.8 percent of the variation in dietary fat. The primary analysis, an inverse variance weighted method, found that each standard deviation increase in genetically predicted fat intake was associated with 28 percent higher odds of portal hypertension, an odds ratio of 1.28 with a 95 percent confidence interval of 1.15 to 1.42 and a p-value of 1.0 times ten to the minus five.

Crucially, the association held up across every complementary method the team applied. The weighted median estimator, which remains valid even if up to half of the instruments are faulty, produced an odds ratio of 1.23. MR-Egger regression, designed to detect directional pleiotropy, where variants affect the outcome through pathways other than the exposure, yielded 1.35, and its intercept test showed no evidence of such pleiotropy. Cochran’s Q statistic found no significant heterogeneity among the SNP estimates, and the MR-PRESSO outlier-detection procedure identified no pleiotropic outliers, with the outlier-corrected estimate virtually identical to the original. A leave-one-out analysis confirmed that no single genetic variant was driving the result, and a Steiger directionality test verified that the causal arrow runs from diet to disease rather than the reverse. An independent FinnGen analysis of nearly 400,000 Finns, using liver cirrhosis as a surrogate endpoint with zero participant overlap, replicated the direction and significance of the effect.

The clinical arm of the study grounded these genetic findings in measurable physiology. The researchers retrospectively studied 72 patients with chronic liver disease who underwent hepatic venous pressure gradient, or HVPG, measurement at a tertiary hepatology center between 2021 and 2023. HVPG, the difference between wedged and free hepatic venous pressures, is the gold standard for assessing portal pressure, with values above 5 mmHg defining portal hypertension and values at or above 10 mmHg defining clinically significant disease. Dietary intake was assessed with a validated 168-item food frequency questionnaire administered by trained staff, and a high-fat diet score from 0 to 10 was calculated from consumption of red and processed meats, high-fat dairy, fried foods, cooking oils, and nuts and seeds.

The correlation was striking. The high-fat diet score correlated with HVPG at r = 0.700, and patients in the highest tertile of fat intake had a mean HVPG of 14.53 mmHg, compared with 12.29 mmHg in the moderate group and 9.37 mmHg in the low-fat group, a gap of roughly 5 mmHg between the extremes. The clinical stakes of that gap are considerable, because each 1 mmHg increase in HVPG is associated with approximately 10 to 15 percent higher risk of variceal bleeding, and even reductions of 2 to 3 mmHg are considered clinically meaningful. Nearly 94 percent of the high-fat diet group had clinically significant portal hypertension, versus only about 42 percent of the low-fat group.

Importantly, the association survived statistical adjustment. In a multivariate linear regression controlling for age, sex, BMI, bilirubin, albumin, and platelet count, each one-point increase in the high-fat diet score predicted a 0.85 mmHg increase in HVPG, and a partial correlation adjusting for BMI alone remained significant. That finding suggests dietary composition matters beyond its effect on body weight, consistent with emerging evidence that saturated and trans fats can exert direct hepatotoxic effects independent of overall adiposity. The regression model explained 62.3 percent of the variance in HVPG, and cross-validation and bootstrap correction confirmed it retained good predictive performance despite the modest sample size.

The authors stress that they did not directly test mechanisms, but several plausible biological pathways could connect fatty diets to raised portal pressure, all drawn from prior literature and acknowledged as speculative. Hepatic steatosis, the accumulation of fat inside liver cells, may increase intrahepatic vascular resistance by compressing sinusoids and reducing vascular compliance. Lipotoxicity from saturated fatty acids can trigger oxidative stress, endoplasmic reticulum stress, and activation of hepatic stellate cells, the cells that drive fibrosis. High-fat diets may also disrupt the gut microbiome and increase intestinal permeability, flooding the liver with bacterial endotoxin and fueling inflammation, while the associated insulin resistance can raise hepatic vascular tone by impairing nitric oxide signaling.

The study has real limitations, and the researchers are candid about them. Mendelian randomization captures the effect of lifelong genetic predisposition, which may not translate directly into the benefits of moderate dietary changes adopted in adulthood. The genetic analysis was restricted to people of European ancestry, the dietary data relied on self-reported questionnaires, and the clinical cohort was small and drawn from a single center with a retrospective design. The diet score also did not distinguish saturated from unsaturated fats. Even so, the convergence of genetic and clinical evidence on the same conclusion gives the finding unusual weight, and the authors argue it provides a rationale for testing dietary fat reduction as a potential adjunctive strategy for managing portal hypertension, pending confirmation in prospective intervention trials. For now, the message is a cautious one: what lands on the plate may help determine the pressure inside the portal vein.

Subject of Research: Causal relationship between high-fat diet and portal hypertension assessed by Mendelian randomization and clinical HVPG measurement

Article Title: High-fat diet and portal hypertension: a triangulation approach combining Mendelian randomization with retrospective clinical analysis

Article References: Xu, Y., Yang, S., Li, Y., Han, Q., & Wang, W. (2026). High-fat diet and portal hypertension: a triangulation approach combining Mendelian randomization with retrospective clinical analysis. Frontiers in Gastroenterology, 5, Article 1927449. https://doi.org/10.3389/fgstr.2026.1927449

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1927449

Keywords: portal hypertension, high-fat diet, Mendelian randomization, hepatic venous pressure gradient, liver disease, causal inference, NAFLD, cirrhosis, GWAS, dietary fat, triangulation, hepatology

The stakes of the research are considerable. According to data cited by the authors, roughly 890 million people worldwide live with obesity and 589 million adults aged 20 to 79 live with diabetes, while nearly 197 million more suffer from impaired glucose tolerance. Modern Western dietary patterns, dominated by calorie-dense, high-fat and processed foods, drive much of this crisis. Crucially, scientists now view obesity not merely as an over-accumulation of fat but as a state of chronic, low-grade tissue inflammation. That inflammation fuels insulin resistance, which in turn progresses toward type 2 diabetes, and it disrupts the regulation of metabolic hormones such as leptin and adiponectin that normally keep appetite and energy balance in check.

To model this pathology, the team turned to the workhorse of metabolic research: the high-fat diet mouse. Forty Swiss albino mice, each weighing about 23 grams and aged six to eight weeks, were randomly assigned to five groups of eight animals. One group received a normal diet, one received a high-fat diet deriving 60 percent of its calories from fat, and three treatment groups ate the high-fat diet while receiving curcumin at 90 milligrams per kilogram of body weight, disulfiram at 200 milligrams per kilogram, or both compounds together by oral gavage over 12 weeks. The researchers then tracked food intake, body weight, the Lee obesity index, fasting glucose, glycated hemoglobin, glucose tolerance, serum insulin and leptin, lipid profiles, liver enzymes, and liver histology.

The results on food intake and body weight were dramatic. From the fifth week onward, high-fat diet mice treated with either compound ate significantly less food; by week 12, curcumin-treated mice had consumed 16.76 grams and disulfiram-treated mice 17.68 grams, compared with 23.54 grams in the untreated high-fat group. The combination group ate even less, roughly 32 percent below the high-fat-only animals and lower than even the normal chow controls. Body weight followed the same pattern. The untreated high-fat mice ballooned to a mean of 36.70 grams, nearly 40 percent heavier than controls, while the curcumin group reached only 28.28 grams, a 22.94 percent reduction in weight gain, the largest numerical drop of any intervention. The combination stabilized around 29.32 grams and disulfiram alone at 29.40 grams.

Metabolic measurements reinforced the picture. The Lee obesity index, a standard morphometric gauge of adiposity, climbed above 310 in the untreated high-fat mice but stayed below that threshold in all three treated groups. Fasting blood glucose in the high-fat group reached 230 milligrams per deciliter, more than double the control value of 112.67, and glycated hemoglobin rose more than two-fold to 6.55 millimoles per mole, confirming long-term hyperglycemia and type 2 diabetes. Here the synergy became unmistakable: curcumin and disulfiram monotherapies each lowered HbA1c, but the combination brought it down to 4.68 millimoles per mole, the value closest to the control baseline of 3.10.

Glucose tolerance testing told a similar story. Untreated high-fat mice began the oral glucose tolerance test at nearly double the control baseline glucose and remained highly elevated even after 120 minutes, with an area under the curve almost 54 percent larger than controls. Both monotherapies restored 120-minute glucose to around 108 milligrams per deciliter, but the combination group cleared the glucose load fastest, peaking at just 165 milligrams per deciliter at 15 minutes and falling to 123 by the two-hour mark while maintaining the most stable overall profile. The hormonal data were equally striking. Untreated high-fat mice showed roughly five-fold elevated insulin and a six-fold increase in the HOMA-IR index of insulin resistance, along with leptin levels of 13.28 nanograms per milliliter versus 4.27 in controls, hallmarks of compensatory insulin hypersecretion and leptin resistance. The combination treatment restored insulin almost entirely to the control baseline of 0.76 nanograms per milliliter and cut leptin to 6.01, outperforming either drug alone.

The liver, a central casualty of diet-induced obesity, also benefited. Untreated high-fat mice developed severely deranged lipid profiles, with triglycerides of 120.54 milligrams per deciliter and cholesterol of 208.23 versus control values of 96.20 and 92.20 respectively, alongside sharply elevated LDL and depressed HDL. The combination treatment brought all four lipid parameters back to levels statistically indistinguishable from controls. Liver injury enzymes told the same tale: serum SGPT rose from 42.96 to 87.28 units per liter and SGOT from 70.18 to 152.40 in the high-fat group, but the combination drove SGPT down to 43.99, essentially the control value, and SGOT to 105.93, better than either monotherapy. Under the microscope, the untreated high-fat livers showed inflammatory cell infiltration, ballooning hepatocytes, and extensive intracellular fat droplets, while the combination-treated livers regained an architecture closely resembling healthy tissue, with only mild sinusoidal dilations persisting.

Mechanistically, the two compounds attack obesity from complementary angles. Disulfiram, historically known as Antabuse, inhibits aldehyde dehydrogenase, and because the ALDH1A1 enzyme participates in retinoic acid biosynthesis and energy homeostasis, blocking it promotes weight loss. The drug has also been shown to suppress the NLRP3 inflammasome, a key driver of chronic inflammation and insulin resistance, and to activate autophagy, improving glucose handling. Curcumin, meanwhile, deploys phenolic hydroxyl groups with potent antioxidant activity that protect the liver and pancreas, and it activates AMP-activated protein kinase, a cellular fuel gauge that promotes glucose uptake in muscle, stimulates fatty acid oxidation, and inhibits gluconeogenesis in the liver. Together, reduced appetite, dampened inflammation, and improved glucose and fat metabolism appear to reinforce one another.

The authors are careful to note that enthusiasm must be tempered by caveats. The 200 milligrams per kilogram disulfiram dose used in mice converts, by standard body surface area methods, to roughly 1,000 milligrams per day in humans, well above the FDA-approved maximum of 500 milligrams per day, and disulfiram has been associated with neurological and psychological adverse events. Curcumin, for its part, suffers from poor bioavailability, limiting how much active compound actually reaches tissues. The team calls for comprehensive toxicological assessment of disulfiram and for advanced delivery methods, such as the nanoparticle formulations already showing promise in vitro, to improve curcumin’s clinical utility. The study was approved by the Institutional Animal Ethical Committee at Banaras Hindu University.

Still, as a proof of concept, the findings are compelling. Mice eating an obesity-inducing diet stayed lean, kept their glucose tolerance, normalized their hormones and blood fats, and protected their livers, all with two inexpensive and widely available compounds, one of them sitting in the spice rack. If future work can resolve the safety and bioavailability questions, the curcumin-disulfiram pairing could offer a cost-effective preventive strategy against the intertwined epidemics of obesity and type 2 diabetes, a goal that conventional single-drug approaches have struggled to achieve.

Subject of Research: Synergistic anti-obesity effects of curcumin and disulfiram in high-fat diet-fed mice

Article Title: Anti-obesogenic potential of curcumin, disulfiram, and their synergistic effects in HFD-fed obese Swiss albino mice

Article References: Patel, J. K., More, R. S., Singh, A. N., & Gupta, A. (2026). Anti-obesogenic potential of curcumin, disulfiram, and their synergistic effects in HFD-fed obese Swiss albino mice. Frontiers in Endocrinology, 17, Article 1954754. https://doi.org/10.3389/fendo.2026.1954754

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1954754

Keywords: curcumin, disulfiram, obesity, type 2 diabetes, high-fat diet, insulin resistance, leptin, fatty liver, drug repurposing, mouse model, metabolic syndrome, HOMA-IR

The study, led by Linmei Liu, Hongzhe Zeng, and colleagues at Hunan Agricultural University in China, compared Shoumei white teas sourced from Zhenghe County in Fujian province. Chemical profiling revealed substantial storage-associated differences. The aged white tea contained significantly higher concentrations of gallic acid, caffeine, thearubigins, and theabrownin, reflecting the slow oxidative polymerization of catechins into larger pigmented molecules over time. The newly produced tea, by contrast, was richer in total tea polyphenols, free amino acids, theobromine, and intact monomeric catechins, including roughly double the epigallocatechin gallate (EGCG) found in the aged sample. Untargeted metabolomics using ultra-performance liquid chromatography coupled to mass spectrometry identified 112 compounds across the two infusions, with six showing statistically significant accumulation differences. Two galloylated glucose derivatives and L-glutamine were enriched in the new tea, while guanine, cytosine, and nicotinic acid were more abundant in the aged tea.

To test the biological consequences of these compositional shifts, the researchers fed six-week-old male C57BL/6J mice a diet in which sixty percent of calories came from fat, a standard model for inducing obesity and metabolic syndrome. The animals were divided into four groups of eight: one received standard chow with plain water, one received the high-fat diet with plain water, and the remaining two received the high-fat diet with unlimited access to either the aged or the new white tea infusion as their drinking water. Notably, the team chose ad libitum access to tea infusions rather than the intragastric gavage used in many previous studies, because forced administration can damage the bioactivity of plant compounds and provoke stress responses in animals that disturb glucose-lipid homeostasis and confound the results. The free-access approach also more closely mirrors how people actually drink tea.

Over the four-week intervention, both teas significantly counteracted the high-fat diet’s effects. Obese model mice displayed elevated final body weight, a higher Lee’s index of adiposity, enlarged subcutaneous and epididymal fat depots, increased food and energy intake, and greater energy efficiency. Both tea treatments lowered body weight, reduced adipose tissue masses, and restored a more compact body conformation, with visibly reduced abdominal fat deposition. The newly produced tea, however, achieved a significantly greater reduction in final body weight than the aged tea and showed a stronger capacity to lower energy efficiency, the fraction of consumed energy retained by the animal. Fluid intake was lower in the tea groups, likely reflecting transient behavioral accommodation to the sensory properties of the infusions, but the researchers confirmed that comparable consumption between the two tea groups validated the dose equivalence of the comparison.

Glucose homeostasis improved under both interventions. The high-fat diet produced hyperglycemia, hyperinsulinemia, and insulin resistance, as shown by elevated fasting blood glucose, elevated fasting serum insulin, and a higher homeostatic model assessment of insulin resistance index. Both teas significantly blunted these increases, indicating improved insulin sensitivity. The lipid picture was more revealing of the teas’ differences. Both lowered serum total cholesterol and LDL-cholesterol, but the aged tea achieved a significantly greater LDL reduction than the new tea. In the liver, the aged tea also significantly reduced hepatic cholesterol and serum aspartate aminotransferase, a marker of liver cell injury, whereas the new tea did not significantly alter these parameters relative to the untreated obese group. Histological examination of liver sections showed severe macrovesicular steatosis in untreated obese mice, with extensive fat droplets crowding the tissue, while both teas markedly reduced the number and size of lipid droplets.

Serum metabolomics helped explain what was happening systemically. The high-fat diet dramatically remodeled the serum metabolome, with 115 metabolites differing between lean and obese controls. Both teas partially normalized this disturbance, with glycerophospholipid metabolism emerging as a prominently affected pathway in multiple comparisons. Three metabolites in that pathway—1-hexadecyl-sn-glycero-3-phosphocholine, glycerophosphocholine, and choline—rose on the high-fat diet and fell in response to both teas. But each tea also carried a distinct metabolic signature: the aged tea significantly increased serum azelaic acid, a metabolite linked in prior research to lipolysis, lipid peroxidation, and inflammatory regulation, while the new tea significantly raised betaine, a compound previously shown in experimental studies to limit high-fat-diet-induced weight gain and adipose accumulation.

The gut microbiota emerged as a central player. Sixteen-ribosomal-RNA-gene sequencing of cecal contents showed that the high-fat diet significantly restructured microbial communities, reducing alpha-diversity, shifting community composition in principal coordinate analysis, and raising the abundance of Firmicutes. Both teas tended to restore diversity indices and lowered serum lipopolysaccharide, a marker of metabolic endotoxemia arising from compromised intestinal barrier function, with the aged tea producing the larger decrease in circulating LPS and a more consistent improvement across the richness and diversity measures. At the genus level, both teas reduced four candidate taxa—Solibacillus, Candidatus Saccharimonas, Adlercreutzia, and Faecalibaculum—that correlated positively with fat mass, fasting insulin, and cholesterol in the obese mice. The decisive divergence came from two other genera: the aged tea selectively increased Lachnospiraceae_NK4A136_group, a taxon associated with short-chain fatty acid production, while the new tea selectively enriched Akkermansia, a genus famous in microbiome research for its inverse associations with obesity.

Correlation analysis wove these threads together. The aged tea’s enriched constituents—gallic acid, theaflavins, guanine, thearubigins, nicotinic acid, caffeine, theabrownin, and cytosine—correlated positively with Lachnospiraceae_NK4A136_group and with azelaic acid, while the genus itself correlated negatively with LDL-cholesterol, serum LPS, and the liver injury marker AST. This suggests the aged tea’s hepatoprotective profile may operate through a gallic-acid-driven axis that restores Lachnospiraceae_NK4A136_group and boosts azelaic acid, though the short-chain fatty acid mechanism remains hypothetical because those metabolites were not directly quantified. The new tea’s abundant catechins, polyphenols, free amino acids, and theobromine instead correlated positively with betaine, which itself inversely tracked fasting blood glucose, body weight, fat pad masses, insulin resistance, and LDL-cholesterol—identifying betaine as a plausible intermediary for the new tea’s superior weight-lowering effect. Curiously, Akkermansia enrichment did not correlate with most metabolic endpoints in this study, leaving its role in the new tea’s phenotype an open question.

The findings carry an intriguing implication for consumers and researchers alike: the value of aged tea is not simply a faded version of fresh tea but a chemically transformed product with its own biological identity. Oxidative polymerization of catechins into theaflavins, thearubigins, and theabrownins over ten years of storage appears to shift the tea’s activity from body-weight regulation toward hepatic lipid homeostasis and endotoxin control. The authors caution, however, that their conclusions rest mainly on multi-omics correlation analysis and prior work from their group, so causality between the compound-microbe-metabolite relationships and the observed phenotypes is not yet established. They call for follow-up studies using fecal microbiota transplantation, targeted metabolite interventions, and germ-free animal models to confirm the proposed pathways.

For now, the study stands as one of the most comprehensive direct comparisons of aged versus newly produced white tea, combining phytochemical characterization, physiology, histopathology, serum metabolomics, and microbiome sequencing in a single experimental framework. It suggests that in the future, the choice between a young, catechin-rich white tea and a decade-aged, theabrownin-rich one might be tailored to a person’s specific metabolic priorities—weight management on one side, liver and lipid protection on the other. That nuance, emerging from an ordinary cup of tea steeped for five minutes in boiling water, underscores how profoundly storage chemistry and the gut microbiome shape the health effects of what we drink.

Subject of Research: Comparative effects of aged and newly produced white tea on glucose and lipid metabolism and the gut microbiota in obese mice

Article Title: Comparative Effects of Aged and Newly Produced White Tea on Glucose and Lipid Metabolism and the Gut Microbiota in Mice with High-Fat Diet-Induced Obesity

Article References: Liu, L., Zeng, H., Wan, L., Peng, L., Bai, Q., Yang, X., Li, H., Rao, H., Li, L., Xiong, X., Yu, H., Zheng, X., Huang, J., & Liu, Z. (2026). Comparative effects of aged and newly produced white tea on glucose and lipid metabolism and the gut microbiota in mice with high-fat diet-induced obesity. Current Research in Food Science, 13, Article 101597. https://doi.org/10.1016/j.crfs.2026.101597

Image Credits: AI Generated

DOI: 10.1016/j.crfs.2026.101597

Keywords: white tea, obesity, gut microbiota, metabolomics, high-fat diet, insulin resistance, theabrownin, EGCG, betaine, azelaic acid, liver steatosis, glucose metabolism

The research, led by Cassandra E. Gheorghe and Juliette Montet of the NutriNeuro laboratory at the University of Bordeaux, together with colleagues at INRAE and clinical partners in the Bordeaux region, set out to test whether disruptions in mitochondrial energy metabolism might help explain the comorbidity between obesity and neuropsychiatric symptoms. While chronic low-grade inflammation has been the dominant explanation in the literature for years, the authors argue that additional immunometabolic alterations, particularly those affecting the tricarboxylic acid (TCA) cycle, may play a significant and previously underappreciated role.

The TCA cycle, also known as the Krebs cycle or citric acid cycle, is a sequence of biochemical reactions that takes place inside mitochondria, the organelles often described as cellular power plants. The cycle oxidizes nutrients derived from carbohydrates, fats, and proteins, generating intermediate metabolites such as citrate, succinate, and malate, which feed the electron transport chain that ultimately produces adenosine triphosphate, the universal energy currency of cells. Because the brain is among the most energetically demanding organs in the body, even subtle perturbations in this machinery could, in principle, influence mood, motivation, and the subjective sense of vitality.

To investigate this possibility, the research team adopted a dual approach that combined human clinical data with animal experiments, a design that strengthens the translational relevance of the findings. On the clinical side, they recruited 83 adults with obesity, defined as a body mass index above 30 kilograms per square meter, and measured the circulating levels of TCA cycle metabolites in their blood plasma. Crucially, they did not stop at metabolic measurements. Each participant also completed validated psychometric assessments: the Montgomery-Asberg Depression Rating Scale for depressive symptoms, the state form of the State-Trait Anxiety Inventory for anxiety, and the Multidimensional Fatigue Inventory for fatigue.

The results revealed a striking pattern. Lower levels of circulating TCA cycle metabolites were associated with more severe neuropsychiatric symptoms in the obese participants, with the strongest and most consistent associations observed for fatigue and reduced motivation. In other words, the individuals whose blood showed the most pronounced depletion of these key metabolic intermediates were also the ones reporting the greatest exhaustion and diminished drive. Interestingly, the associations differed across symptom dimensions, suggesting that distinct aspects of the TCA cycle may map onto different neuropsychiatric phenotypes rather than a single undifferentiated state of psychological distress.

Correlation in humans, however, is only half the story. To probe whether these metabolic shifts have a causal or mechanistic connection to behavior, the team turned to a preclinical model. Male C57BL/6J mice were chronically exposed to a high-fat diet, a standard experimental paradigm for inducing obesity and its metabolic consequences. The researchers then assessed depressive-like behavior using the sucrose preference test, which measures anhedonia, the reduced ability to experience pleasure, and the forced swim test, a widely used index of behavioral despair. Anxiety-like behavior was evaluated with the elevated plus-maze, which exploits the natural conflict between a rodent’s curiosity and its aversion to open, exposed spaces.

Alongside these behavioral measures, the team quantified TCA cycle metabolite levels not only in the plasma but also in three discrete brain regions: the striatum, the hippocampus, and the frontal cortex. This regional analysis proved to be one of the most compelling aspects of the study. The preclinical data identified region-specific associations between brain TCA cycle metabolite levels and behavioral outcomes, and these associations appeared to be modulated by exposure to the high-fat diet. Each of the three regions examined plays a distinct role in emotional and motivational processing. The hippocampus is central to stress regulation and is consistently implicated in depression, the frontal cortex governs executive control and mood regulation, and the striatum is a hub of the reward circuitry that underlies motivation and pleasure seeking.

The finding that metabolic signatures in these specific circuits correlate with specific behavioral outputs lends biological plausibility to the human data. A metabolite profile in the striatum that tracks with anhedonia-like behavior, for example, would align neatly with the clinical observation that reduced motivation was among the symptoms most tightly linked to altered circulating metabolites. Although the study, by design, cannot definitively establish causation in humans, the convergence of the clinical and preclinical arms provides what the authors describe as novel evidence linking TCA cycle dysregulation to neuropsychiatric comorbidities in obesity, and it highlights specific metabolites as potential targets of interest for future research.

The implications of this work extend in several directions. First, it reframes obesity-related neuropsychiatric symptoms not merely as psychological reactions to weight, stigma, or social difficulties, but as phenomena with a measurable biochemical substrate rooted in mitochondrial metabolism. Second, it suggests that the long-standing focus on inflammation, while valuable, may capture only part of the immunometabolic picture. Mitochondrial function and inflammatory signaling are deeply intertwined, and metabolites of the TCA cycle themselves act as signaling molecules that can regulate immune cell behavior. Disruptions in the cycle could therefore feed back into the inflammatory processes already implicated in mood disorders, creating a self-reinforcing loop.

Third, the study opens the door to potential biomarker development. If specific circulating TCA cycle metabolites reliably track fatigue and motivational deficits in people with obesity, they could eventually serve as objective markers to identify patients at heightened neuropsychiatric risk, stratify them for targeted interventions, and monitor treatment response. Nutritional, pharmacological, or lifestyle strategies aimed at restoring mitochondrial metabolic function might then be evaluated in a more precise and personalized manner. The work was supported by the French National Research Institute for Agriculture, Food and Environment and by international funding programs dedicated to nutrition and health biomarkers, reflecting a growing institutional commitment to understanding how metabolism shapes mental health.

Important caveats remain. The clinical cohort was modest in size, and cross-sectional associations cannot determine whether reduced TCA cycle metabolite levels precede the neuropsychiatric symptoms or result from them. Fatigue and low motivation can themselves alter eating patterns, physical activity, and sleep, all of which influence mitochondrial metabolism. The preclinical experiments, while informative, used male mice only, leaving open questions about sex differences that are highly relevant given the epidemiology of both obesity and depression. Moreover, the human measurements were restricted to blood, so the extent to which circulating metabolite levels faithfully reflect what is happening inside the brain remains an active area of investigation, even though the animal data on brain-region-specific metabolite profiles provide valuable supporting evidence.

Nevertheless, the study represents a meaningful step forward in a field that has struggled to explain why so many individuals with obesity experience depression, anxiety, and exhaustion that cannot be fully accounted for by inflammation or psychosocial factors. By shining a light on the tricarboxylic acid cycle, the Bordeaux team has connected two research territories that rarely speak to each other: classical mitochondrial biochemistry and modern neuropsychiatric epidemiology. The metabolites they identified as being of potential interest now become candidates for longitudinal studies, intervention trials, and mechanistic follow-up work in both rodents and humans.

As the global prevalence of obesity continues to climb, and with it the burden of obesity-related mental health problems, research of this kind underscores a simple but powerful idea: the health of the mind may depend, in part, on the metabolic health of the cell. The mitochondria that power our muscles and organs also power our brains, and when their core metabolic machinery falters under the chronic metabolic stress of obesity, the consequences may be felt not only on the scale or in blood panels, but in mood, motivation, and the everyday energy needed to live a full life. The next chapter of this research will determine whether restoring the cycle can restore the spirit.

Subject of Research: TCA cycle metabolite disruptions and neuropsychiatric symptoms in obesity

Article Title: Translational evidence of tricarboxylic acid cycle disruptions in obesity: relevance to neuropsychiatric symptoms

Article References: Gheorghe, C. E., Montet, J., Vancassel, S., Amadieu, C., Leyrolle, Q., Dexpert, S., Beau, C., Forestier, D., Ledaguenel, P., Magne, E., Castanon, N., & Capuron, L. (2026). Translational evidence of tricarboxylic acid cycle disruptions in obesity: relevance to neuropsychiatric symptoms. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04476-7

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04476-7

Keywords: obesity, TCA cycle, mitochondria, depression, anxiety, fatigue, metabolites, neuropsychiatry, high-fat diet, immunometabolism, Translational Psychiatry, motivation

The disease at the centre of the study, metabolic dysfunction–associated steatotic liver disease (MASLD), is now the most prevalent chronic liver condition worldwide. It is closely tied to high-fat diets, gut microbial imbalance and disrupted metabolism, and it carries consequences well beyond the liver. Sustained hepatic metabolic disturbance can spill over into skeletal muscle through inflammation-mediated pathways and abnormal metabolite production, and a growing body of evidence shows that MASLD is accompanied by reduced muscle mass. Because skeletal muscle is the body’s principal site of glucose disposal, its loss promotes insulin resistance, which in turn worsens the liver disease—a vicious cycle that clinicians have few tools to break. Non-pharmacological interventions that could protect both organs at once would therefore be of considerable clinical value.

Yet the fasting literature has been contradictory on precisely this point. Time-restricted feeding in rodents has shown direct benefits for muscle remodelling, but its pattern differs from 5:2 fasting. A murine study using three nonconsecutive 24-hour fasts per week found that intermittent fasting enhanced autophagy in the liver but failed to activate it in skeletal muscle, hinting that muscle might benefit less than the liver. Other work has suggested that combining minimal food intake with prolonged fasting could be unfavourable for muscle protein balance, and some clinical studies report reductions in lean body mass alongside weight loss, even if the decline falls short of true atrophy. Most human trials, moreover, lack comprehensive assessments of skeletal muscle. The new study was designed to address this gap directly by examining liver and muscle outcomes together in the same animals.

The experimental design was straightforward but rigorous. Seven-week-old male C57BL/6J mice were fed either normal chow or a 45% high-fat diet for 14 weeks to induce MASLD, which was confirmed by liver histopathology. The remaining high-fat-fed mice were then randomised by body weight into two groups for a 12-week intervention: one continued the high-fat diet ad libitum, while the other followed the 5:2 regimen, fasting on two nonconsecutive days each week with free access to water and eating the high-fat diet freely on the remaining five days. Crucially, all mice were sacrificed in a fed state—the fasting group 48 hours after its last fast—so that comparisons were not confounded by acute fasting physiology. Grip strength, serum biochemistry, histology, quantitative PCR, targeted fatty acid profiling by gas chromatography–mass spectrometry and faecal metagenomic sequencing rounded out the analytical toolkit.

On the liver side, the results were unambiguous. After 12 weeks, body weight was significantly lower in the fasting group than in the continuously high-fat-fed controls, and serum triglycerides, total cholesterol and the liver enzymes ALT and AST all fell markedly. The liver-to-body-weight ratio declined, gross liver appearance shifted from yellow and steatotic toward healthy, and histopathology confirmed reduced lipid accumulation and inflammation. White adipose tissue depots shrank across omental, subcutaneous, perirenal and epididymal sites. Interestingly, fasting mice showed pronounced compensatory hyperphagia during refeeding, eating more per day than the continuous-diet group, but cumulative weekly food mass and energy intake ended up similar between the two groups—the feasting apparently offset the fasting. Blood glucose did not differ significantly between the groups, a finding the authors attribute to that same compensatory intake during the refeeding phase.

The muscle findings are what set this study apart. Long-term high-fat feeding significantly shrank the cross-sectional area of quadriceps muscle fibres and reduced grip strength normalised to body weight, confirming that MASLD is accompanied by genuine muscle impairment rather than mere weight gain masking muscle loss. After the fasting intervention, absolute quadriceps mass was not significantly higher than in the high-fat group, but the muscle-to-body-weight ratio and body-weight-normalised grip strength rose markedly and returned to levels comparable with normal-chow mice. Linear regression revealed a significant positive correlation between body weight and muscle mass only in the high-fat group, indicating that weight gain there far outpaced any muscle growth. Expression of the inflammatory cytokine genes Il6 and Tnf in muscle also dropped significantly, and muscle fibre cross-sectional area was significantly larger after fasting than under the continuous high-fat diet.

To explain how a dietary schedule could protect two distant organs, the researchers turned to the gut. Histology showed that the high-fat diet thinned the intestinal wall and drove inflammatory cell infiltration, while fasting restored wall thickness and calmed inflammation. Genes encoding the barrier components Muc2 and the tight junction proteins Tjp1, Cldn4 and Ocln were downregulated by the high-fat diet and upregulated by fasting, and serum lipopolysaccharide—a marker of microbial endotoxin leaking through a damaged barrier—was elevated in high-fat mice but normalised by the intervention. Metagenomic sequencing of faecal samples then revealed that fasting reshaped the microbial community structure toward that of healthy chow-fed mice, without changing overall diversity. The pro-inflammatory species Mucispirillum schaedleri dominated in high-fat mice, whereas the fasting group was enriched in beneficial taxa including Faecalibaculum rodentium and Limosilactobacillus reuteri, and functional analysis pointed to enhanced bacterial capacity for secondary bile acid biosynthesis and bile salt hydrolase activity, with F. rodentium the top contributor.

Bile acids provided the mechanistic thread. Bacteria with bile salt hydrolase activity deconjugate primary bile acids, generating substrates for secondary bile acids that act as signalling molecules on receptors in the intestine, liver and muscle. Consistent with this, fasting upregulated the canonical bile acid receptor Fxr in intestine and liver, and hepatic Fxr suppressed its downstream target Cyp7a1. Hepatic expression of Ppara and its targets Cpt1a and Acox1—drivers of fatty acid beta-oxidation—rose significantly, as did the FGF15 receptor pair Fgfr4 and Klb in both liver and muscle. In skeletal muscle, the bile acid-responsive receptor Tgr5 was upregulated along with Pkaca, while Foxo3 and the atrophy genes Trim63 and Fbxo32—markers of muscle protein breakdown—were significantly repressed. Targeted fatty acid profiling reinforced the picture: total free fatty acid content fell in both liver and muscle to levels indistinguishable from healthy controls, with palmitic acid (C16:0) among the shared fatty acids reduced by fasting. Correlation analyses tied these threads together, showing bile acid receptor genes generally negatively correlated with differential fatty acids, and Tgr5 most strongly negatively correlated with palmitic acid, a saturated fatty acid known to induce tissue inflammation.

The authors are careful about causality. The mechanistic evidence remains largely correlative, and they note that direct proof of bile salt hydrolase activity in F. rodentium is lacking, even though the species has been implicated in converting primary bile acids to secondary forms. Species differences loom large: rodents and humans differ substantially in bile acid composition, microbiota structure and bile salt hydrolase enzymology, and the net effect of elevated bile salt hydrolase activity in human MASLD may be protective or harmful depending on metabolic context. The study also used only male mice, leaving open whether females respond similarly, and the diet-induced mouse model cannot fully recapitulate the heterogeneity of human disease. The authors call for faecal microbiota transplantation, microbiota depletion and mono-colonisation experiments, together with FXR- or TGR5-deficient mice and receptor-specific agonists, to establish whether the microbial changes are necessary and sufficient for the metabolic benefits.

Even with those caveats, the study lands at a moment of intense clinical interest. Recent human trials have found that 5:2 fasting achieves greater reductions in fat mass and glycated haemoglobin in MASLD patients than continuous energy restriction, without compromising lean body mass, and rodent work has shown it attenuates Western diet-induced steatohepatitis. The new findings extend that picture by demonstrating, in the same animals, coordinated protection of liver and skeletal muscle and a plausible gut–liver–muscle axis linking barrier integrity, microbial bile acid metabolism, receptor signalling and lipid handling. The authors emphasise that clinical translation will require trials in MASLD patients that measure not only hepatic outcomes but also muscle quality, strength, dietary intake, microbiota composition and bile acid profiles—particularly in elderly, diabetic or sarcopenic patients at risk of insufficient protein intake, who may respond differently to fasting. If those trials succeed, the humble schedule of two fasting days a week could emerge as a lifestyle intervention that defends the liver and the muscle at the same time.

Subject of Research: Effects of 5:2 intermittent fasting on MASLD and skeletal muscle impairment in mice via gut microbiota and bile acid signalling

Article Title: A 5:2 Intermittent Fasting Regimen Ameliorates High‐Fat Diet‐Induced MASLD‐Associated Skeletal Muscle Impairment in Mice

Article References: Wang, R., Yang, R., Hu, D., Xin, T., Yang, Z., Guan, Y., & Niu, Y. (2026). A 5:2 Intermittent Fasting Regimen Ameliorates High‐Fat Diet‐Induced MASLD‐Associated Skeletal Muscle Impairment in Mice. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70398. https://doi.org/10.1002/jcsm.70398

Image Credits: AI Generated

DOI: 10.1002/jcsm.70398

Keywords: intermittent fasting, 5:2 diet, MASLD, fatty liver disease, skeletal muscle, gut microbiota, bile acids, high-fat diet, intestinal barrier, muscle atrophy, mice study, metabolic health

The experiment was carefully constructed to separate two questions that are often tangled together: does too much food harm the ovary, or does the wrong kind of food? Three-month-old C57BL/6 mice, the laboratory equivalent of young adulthood, were divided into four groups of twelve. One group received a standard control diet. A second received a low-calorie version of a Western diet, engineered to carry the same saturated fats, refined sugars, and high-glycemic carbohydrates as a typical Western diet but at a lower energy density. A third ate a full Western diet, and a fourth a conventional high-fat diet. All animals ate freely for seventeen weeks, roughly the span from three to seven months of age, while researchers tracked body mass, food intake, metabolic health, reproductive cycling, and ovarian architecture.

The metabolic results followed a predictable gradient. Mice on the full Western diet and the high-fat diet gained progressively more weight than controls, with significant divergence appearing by week three in the high-fat group and week seven in the Western diet group. Intra-abdominal fat mass rose sharply in both groups, and total caloric intake was higher than in the control and low-calorie Western diet groups. Insulin and glucose tolerance tests told a consistent story: high-fat diet mice showed the blunted glucose clearance and reduced insulin responsiveness, with Western diet animals falling in between. Liver histology revealed mild steatotic changes, and serum cholesterol climbed in both high-calorie groups. Yet the most striking metabolic surprise came from the low-calorie Western diet mice, who ate no more calories than controls but still developed elevated fasting glucose, higher liver weights, and worse histological liver scores.

That surprise became central when the researchers turned to the ovary. Using Picrosirius Red staining to visualize collagen, they found that mice on the Western and high-fat diets had significantly increased collagen deposition in the ovarian stroma compared with controls. The low-calorie Western diet group landed squarely in between, statistically indistinguishable from both the controls and the high-calorie groups. Because these animals consumed no more energy than the control mice, the result implies that dietary composition, the saturated fats, refined sugars, and high-glycemic carbohydrates themselves, can drive fibrotic remodeling of the ovary even without caloric excess. The authors caution that this intermediate finding needs confirmation with larger cohorts, but its implications are difficult to ignore.

Why does stromal collagen matter? The ovarian stroma is not passive packing material. It houses the blood vessels, immune cells, and signaling networks that nourish follicles and mediate the constant crosstalk between oocytes, granulosa cells, and the vasculature. As collagen accumulates, the tissue stiffens, disrupting the paracrine signals that folliculogenesis depends on. Previous work has shown that age-associated collagen buildup and fibroblast senescence impair this communication, and, crucially, that interventions which remove fibrotic collagen from the mouse ovary can restore ovulation and extend reproductive lifespan. Fibrosis, in other words, may not simply be a scar left behind by ovarian aging; it may be an upstream driver of it.

The new study adds a dietary dimension to that framework. Alongside collagen, the researchers measured lipofuscin, the indigestible sludge of oxidized proteins and lipids that accumulates in senescent cells and is increasingly recognized as an early marker of ovarian aging. Western diet mice showed significantly more lipofuscin than controls, with the other dietary groups falling in between. Macrophage infiltration, assessed by CD68 immunofluorescence, trended upward in the dietary intervention groups but did not reach statistical significance, leaving the inflammatory component of the remodeling an open question for future work with larger samples.

What the diets did not do is equally informative. Follicle counts across primordial, transitional, secondary, and tertiary categories were largely preserved, and the total number of oocytes ovulated after hormonal superovulation was unchanged. Fluorescent staining of isolated oocytes for lipid content and mitochondrial activity showed no detectable differences across the groups. The only follicular exception was a reduced number of primary follicles in the high-fat diet mice, hinting at diminished follicle survival rather than a wholesale collapse of the reserve. Oocyte quality endpoints such as meiotic spindle integrity and embryo development were not assessed, so subtle damage cannot be ruled out, but on the measures taken, the germ cell compartment looked remarkably resilient while the tissue around it visibly changed.

Reproductive cycling told a more nuanced story. Mice on the full Western diet spent more time in metaestrus and had significantly shorter estrous cycles than controls, a pattern the authors interpret as possible dysregulation of the hypothalamic-pituitary-ovarian axis rather than heightened reproductive activity. The observation echoes human data: short-term high-fat feeding in normal-weight women suppresses luteinizing hormone secretion, and high-glycemic diets are associated with ovulatory disorders, while low-glycemic diets improve menstrual regularity in polycystic ovary syndrome. All three intervention groups in the mouse study also showed elevated fasting glucose, and chronic hyperglycemia is known to disrupt GnRH pulsatility and provoke ovarian inflammation. Because circulating reproductive hormones were not measured, direct endocrine proof is still missing, but the concordance between shortened cycles, elevated glucose, and stromal fibrosis in the Western diet group is suggestive.

The study’s limitations are acknowledged candidly by its authors. Seventeen weeks in young mice is a short window, there was no aged comparator group to separate diet effects from physiological aging, and the single-timepoint design cannot establish whether fibrotic remodeling precedes or follows the metabolic disturbances. Histology was not backed by molecular quantification of extracellular matrix genes or biochemical collagen assays. And because the mice were middle-aged rather than near the end of reproductive life, longer interventions might yet reveal follicular depletion that this experiment could not capture. These caveats temper but do not diminish the central message: the stromal compartment responds to dietary stress earlier and more visibly than the follicles it supports.

The translational horizon is where the findings become genuinely exciting. If ovarian fibrosis is an early and modifiable feature of reproductive decline, then metabolic interventions could plausibly protect fertility. GLP-1 receptor agonists such as semaglutide, already reshaping the treatment of obesity and metabolic disease, may mitigate the upstream conditions that drive ovarian remodeling, and early clinical studies are examining their effects on reproductive outcomes in women with obesity. On the tissue side, the anti-fibrotic drug pirfenidone has been shown in reproductively aged and obese mice to reduce ovarian collagen deposition and improve ovulatory function. The Brazilian team’s work strengthens the case that reproductive aging is not merely a countdown written in the genome but a metabolically responsive process, one in which the food environment writes the earliest chapters, and in which the stroma, not the egg, may hold the first editable draft.

Subject of Research: How dietary composition and metabolic stress reshape the aging ovarian microenvironment in mice

Article Title: Dietary composition and metabolic stress differentially affect the ovarian microenvironment in mice

Article References: da Cunha Pereira, G., Pereira, T. H. L., Prosczek, J. B., Magalhães, L. S., Pinzón-Osorio, C. A., Nogueira, Â. G. A., Hense, J. D., Zanini, B. M., Garcia, D. N., Mondadori, R. G., Vaucher, R. A., & Schneider, A. (2026). Dietary composition and metabolic stress differentially affect the ovarian microenvironment in mice. GeroScience. https://doi.org/10.1007/s11357-026-02530-2

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02530-2

Keywords: ovarian aging, ovarian fibrosis, Western diet, high-fat diet, ovarian reserve, stromal collagen, lipofuscin, estrous cycle, insulin resistance, reproductive longevity, extracellular matrix, GeroScience

Metabolic syndrome, the cluster of obesity, insulin resistance, dyslipidemia, and hypertension that now affects a substantial fraction of adults worldwide, has long been associated with impaired semen quality, altered sex hormone profiles, and increased sperm DNA fragmentation. Epidemiological and meta-analytic work has consistently documented poorer sperm parameters in men with metabolic dysfunction, yet clinical management of metabolic syndrome rarely considers fertility as an outcome, and no targeted therapy exists for the reproductive damage it causes. The research team, led by Yong-Gang Duan and Tao Zhang, set out to ask a question that has remained largely unaddressed: if you treat the metabolic disease itself with a modern metabolic drug, does male reproductive function recover as a consequence?

The drug at the center of the study, obeticholic acid, is a semisynthetic derivative of the natural bile acid chenodeoxycholic acid and one of the most selective agonists known for the farnesoid X receptor, or FXR, a nuclear receptor that acts as a master sensor of bile acid levels. FXR sits at the intersection of bile acid synthesis, lipid metabolism, glucose homeostasis, and immune signaling, and obeticholic acid has already been tested in large clinical trials for nonalcoholic steatohepatitis and approved for primary biliary cholangitis. Because bile acids and their receptor have previously been implicated in testicular development, germ cell fate, and sperm function in mice, the researchers reasoned that FXR activation might reshape the metabolic and inflammatory environment in which sperm mature.

To test this, the team induced metabolic syndrome in male mice by feeding them a high-fat diet for twelve weeks, a standard model that reliably produces obesity, dyslipidemia, and impaired spermatogenesis. The animals then received either obeticholic acid at a dose of 30 milligrams per kilogram or a vehicle control for five weeks. The researchers then measured a comprehensive panel of outcomes: sperm concentration and motility, the immune cell composition of the testis and epididymis, the bile acid profile in the intestine, the composition of the gut microbiota through 16S ribosomal RNA sequencing, and gene expression in the epididymis through RNA sequencing. The raw sequencing data were deposited in public repositories, and the targeted bile acid metabolomics data were archived with the China National Center for Bioinformation, allowing independent verification of the analysis.

The headline result concerned sperm movement. Mice treated with obeticholic acid showed significantly higher progressive motility, the fraction of sperm swimming purposefully in a straight line, which is one of the most clinically meaningful parameters in semen analysis because it reflects the capacity of sperm to reach and penetrate an egg. Progressive motility is particularly vulnerable to oxidative stress and inflammatory damage in the male reproductive tract, and its recovery in the treated animals suggests that the drug was not merely altering body composition but actively improving the functional quality of the sperm themselves. Supplementary analyses showed that the treatment did not significantly change body weight gain or the weights of the testis, epididymis, or epididymal fat, indicating that the reproductive benefit was not simply a byproduct of reduced obesity.

Perhaps the most striking mechanistic finding involved the immune landscape of the epididymis, the coiled duct where sperm complete their maturation and acquire motility. The treated mice had lower proportions of epididymal CD4-positive T helper 1 cells producing interferon-gamma, a pro-inflammatory T cell subset whose accumulation is a hallmark of chronic inflammatory tissue damage. The testis and epididymis are immunologically privileged sites, carefully balanced between tolerance to developing sperm, which express novel antigens after puberty, and defense against pathogens, and metabolic disease is known to tip this balance toward inflammation. By dampening the Th1 response in the epididymis, obeticholic acid appears to have restored a more favorable immune environment for sperm maturation. This immunomodulatory effect is consistent with emerging evidence that FXR signaling can antagonize macrophage-dependent licensing of effector T lymphocytes, a mechanism previously described in the context of sclerosing cholangitis.

The study also documented profound shifts in the gut, the third leg of the proposed mechanism. Obeticholic acid treatment changed the intestinal bile acid pool, altering the relative abundance of specific bile acid species, and simultaneously reshaped the composition of the gut microbiota, the community of bacteria that chemically modifies bile acids and, in turn, is regulated by them. Correlation analyses reported in the supplementary material linked fecal levels of individual bile acids, including lithocholic acid and muricholic acid species, to sperm progressive motility, suggesting that the bile acid signature itself may carry information about reproductive status. This work adds to a growing body of evidence for a gut-testis axis, in which gut-derived metabolites and immune signals influence spermatogenesis, and it echoes earlier findings from the same collaborative network showing that disrupted vitamin A metabolism along this axis contributes to impaired sperm production in metabolic syndrome models.

At the level of individual genes, the epididymal transcriptome revealed a specific molecular casualty of metabolic disease and a specific beneficiary of treatment. Expression of H2bc24, a histone H2B variant gene, was reduced in the high-fat diet mice but rose back to levels comparable with healthy controls after obeticholic acid administration. Histone variants are increasingly recognized as important players in spermatogenesis, where specialized histones must be precisely remodeled to package the paternal genome, and the recovery of this epididymal transcript suggests that the drug partially normalized the gene expression program of the sperm maturation environment. The authors are careful to frame these findings as associations, but the convergence of motility, immune, microbial, bile acid, and transcriptomic endpoints paints a coherent picture of multi-system rescue.

The translational implications are considerable, though the caveats are equally real. Obeticholic acid is a real drug with a known human safety profile, including dose-dependent pruritus and, at higher exposures, concerns about cardiovascular signals that have complicated its path in steatohepatitis trials, so any leap from mice to men would require dedicated reproductive safety and efficacy studies. The mouse model, while standard, cannot fully recapitulate human reproductive physiology, and the five-week treatment window in mice corresponds to roughly one spermatogenic cycle, a timeline that differs substantially between rodents and humans. Nevertheless, the study is the first to systematically test an FXR agonist as a therapy for metabolic syndrome-associated male infertility, and it reframes male reproductive health as a downstream beneficiary of metabolic and gut-targeted medicine rather than an isolated urological problem.

For the millions of men whose metabolic disease may be quietly compromising their fertility, the study offers a proof of concept that the damage may be pharmacologically reversible. It also adds male reproduction to the expanding list of FXR-regulated physiology, joining liver fibrosis, cholesterol homeostasis, and intestinal immunity. If future work confirms that bile acid signaling, Th1 inflammation, and the gut microbiota form a genuine causal pathway from metabolic dysfunction to poor sperm motility, obeticholic acid or related farnesoid X receptor modulators could open an entirely new therapeutic category, one in which treating the gut and the liver ultimately rescues the sperm.

Subject of Research: Effects of the farnesoid X receptor agonist obeticholic acid on male reproductive function in a mouse model of high-fat diet-induced metabolic syndrome

Article Title: Obeticholic Acid Rescues Male Reproductive Function in High-Fat Diet-Induced Metabolic Syndrome

Article References: Liu, J.-C., Zeng, Q., Li, D., Ma, T., Yeung, W. S., Zhang, T., & Duan, Y.-G. (2026). Obeticholic Acid Rescues Male Reproductive Function in High-Fat Diet-Induced Metabolic Syndrome. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02180-x

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02180-x

Keywords: obeticholic acid, farnesoid X receptor, metabolic syndrome, male infertility, sperm motility, bile acids, gut microbiota, epididymis, Th1 cells, high-fat diet, gut-testis axis, H2bc24